NASDAQ: VVOSVivos Therapeutics Inc Stock
$2.57-0.08 (-3.02%)
Updated Apr 24, 2024
VVOS Price
$2.57
Fair Value Price
N/A
Market Cap
$7.02M
52 Week Low
$2.40
52 Week High
$48.79
P/E
-0.23x
P/B
17.08x
P/S
1.1x
PEG
N/A
Dividend Yield
N/A
Revenue
$13.80M
Earnings
-$13.58M
Gross Margin
59.9%
Operating Margin
-98.42%
Profit Margin
-98.4%
Debt to Equity
25.11
Operating Cash Flow
-$12M
Beta
0.9
Next Earnings
Jun 6, 2024
Ex-Dividend
N/A
Next Dividend
N/A
VVOS Overview
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how VVOS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VVOS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
VVOS is poor value based on its book value relative to its share price (17.08x), compared to the US Medical Devices industry average (3.73x)
P/B vs Industry Valuation
VVOS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more VVOS due diligence checks available for Premium users.
Be the first to know about important VVOS news, forecast changes, insider trades & much more!
VVOS News
Valuation
VVOS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.23x
Industry
30.46x
Market
41.27x
VVOS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
17.08x
Industry
3.73x
VVOS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
VVOS's financial health
Profit margin
Revenue
$3.2M
Net Income
-$4.3M
Profit Margin
-131.1%
VVOS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
VVOS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$10.7M
Liabilities
$10.3M
Debt to equity
25.11
VVOS's short-term liabilities ($7.29M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VVOS's long-term liabilities ($3.03M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VVOS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
VVOS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.7M
Investing
-$165.0k
Financing
$3.6M
VVOS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
VVOS vs Medical Device Stocks
Vivos Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.